Information for "Combined 177 LuPSMA617 PRLT along with abiraterone acetate versus 177 LuPSMA617 PRLT monotherapy in metastatic castrationresistant cancer of prostate A great observational examine evaluating the reply and sturdiness"
From EECH Central
Basic information
| Display title | Combined 177 LuPSMA617 PRLT along with abiraterone acetate versus 177 LuPSMA617 PRLT monotherapy in metastatic castrationresistant cancer of prostate A great observational examine evaluating the reply and sturdiness |
| Default sort key | Combined 177 LuPSMA617 PRLT along with abiraterone acetate versus 177 LuPSMA617 PRLT monotherapy in metastatic castrationresistant cancer of prostate A great observational examine evaluating the reply and sturdiness |
| Page length (in bytes) | 3,570 |
| Page ID | 1416093 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Jailcake3 (Talk | contribs) |
| Date of page creation | 11:28, 28 April 2024 |
| Latest editor | Jailcake3 (Talk | contribs) |
| Date of latest edit | 11:28, 28 April 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
